{"url_path":"/sec/anro/8-k/2026-05-13/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1999480/0001999480-26-000014-index.html","accession_number":"0001999480-26-000014","cik":"0001999480","ticker":"ANRO","issuer_name":"Alto Neuroscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1999480/0001999480-26-000014-index.html","primary_entity_key":"0001999480","primary_entity_name":"Alto Neuroscience, Inc."},"word_count":137,"has_tables":true,"body_markdown":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\n(e) Equity Plan Amendments\n\nAs noted in Item 5.07 below, at the Alto Neuroscience, Inc. (the “Company”) 2026 annual meeting of stockholders (the “Annual Meeting”), the Company’s stockholders approved the Amended and Restated 2024 Employee Stock Purchase Plan (the “A&R 2024 ESPP”). The Company’s Board of Directors adopted the A&R 2024 ESPP on March 16, 2026. A full description of the A&R 2024 ESPP appears in the Company’s Definitive Proxy Statement on Schedule 14A (including the annex thereto) filed with the Securities and Exchange Commission on March 26, 2026 (the “Proxy Statement”) and is incorporated herein by reference. A copy of the A&R 2024 ESPP is attached hereto as Exhibit 10.1 and is incorporated herein by reference."}